Metabolism and Pharmacokinetics of JM6 in Mice: JM6 Is Not a Prodrug for Ro-61-8048-Reference-Cited by-同舟云学术

Metabolism and Pharmacokinetics of JM6 in Mice: JM6 Is Not a Prodrug for Ro-61-8048

Published:2012-08-31 Issue:12 Volume:40 Page:2297-2306
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Beconi Maria G.,Yates Dawn,Lyons Kathryn,Matthews Kim,Clifton Steve,Mead Tania,Prime Michael,Winkler Dirk,O'Connell Catherine,Walter Daryl,Toledo-Sherman Leticia,Munoz-Sanjuan Ignacio,Dominguez Celia

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference14 articles.

1. Metabolism of phencyclidine. The role of the carbinolamine intermediate in the formation of lactam and amino acid metabolites of nitrogen heterocycles

2. The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease

3. Quinolinic acid phosphoribosyltransferase in human and rat brain: Activity in Huntington's disease and in quinolinate-lesioned rat striatum

4. Identification of lactams as in vitro metabolites of piperidine-type phenothiazine antipsychotic drugs

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases;European Journal of Medicinal Chemistry;2023-05

2. The Involvement of Kynurenine Pathway in Neurodegenerative Diseases;Current Neuropharmacology;2023-02

3. The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington’s Disease;Journal of Medicinal Chemistry;2022-12-09

4. Kynurenine‐3‐monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression;Journal of Cellular Physiology;2022-09-11

5. Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies;Neuropharmacology;2022-09